In Silico and Intuitive Predictions of CYP46A1 Inhibition by Marketed Drugs with Subsequent Enzyme Crystallization in Complex with Fluvoxamine
about
Structural diversity of eukaryotic membrane cytochrome p450sBinding of a Cyano- and Fluoro-containing Drug Bicalutamide to Cytochrome P450 46A1: UNUSUAL FEATURES AND SPECTRAL RESPONSEAntifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant TherapyPubChem applications in drug discovery: a bibliometric analysisPathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments.Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme ActivityPharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo.Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.,-Dimethyl-3β-hydroxycholenamide Reduces Retinal Cholesterol via Partial Inhibition of Retinal Cholesterol Biosynthesis Rather Than its Liver X Receptor Transcriptional Activity
P2860
Q27025716-F9276536-1BCF-4A0B-B9D7-AFC834F5E1E7Q27675738-1D92569A-1B53-4603-B7BD-7D3DE920126BQ27677470-902DF07F-3CAC-4273-A485-A2020FC8CBD3Q28263601-116C8C29-EDB1-4624-BCEA-079A76A9FE31Q34615684-D35FA7CC-3114-4FA6-862B-15ED68F446DAQ34757496-022AA612-A7E8-4F31-A4CD-30494A1AEBCCQ36941138-5E064338-815F-41E8-8C8F-0C2F9B4A534DQ37563496-E2FD15CE-A576-4780-82F8-1F841D7EE92DQ38713074-14364703-6EB8-46F7-A263-EC95DCFB6D4DQ43226857-AC876680-F252-4847-BC76-461A07834FA3Q47941602-3A8F14C2-E79F-40C3-8BCC-08AEF068110CQ48221935-325B0DCE-134C-4021-B5F9-61CCE7E374E3Q48312809-DBF6AD22-5D8D-4B76-A930-5FAA15BBD507Q57174719-5266F9ED-4CE2-4DA0-B7B8-9E6A1EB96AAD
P2860
In Silico and Intuitive Predictions of CYP46A1 Inhibition by Marketed Drugs with Subsequent Enzyme Crystallization in Complex with Fluvoxamine
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@ast
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@en
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@nl
type
label
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@ast
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@en
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@nl
prefLabel
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@ast
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@en
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@nl
P2093
P2860
P356
P1476
In Silico and Intuitive Predic ...... on in Complex with Fluvoxamine
@en
P2093
C David Stout
Jeffrey Wiseman
Marlin Linger
Matthew Clark
Natalia Mast
P2860
P304
P356
10.1124/MOL.112.080424
P577
2012-11-01T00:00:00Z